Genentech

From Wikipedia, the free encyclopedia - View original article

Genentech, Inc.
TypeWholly owned subsidiary of Roche
IndustryBiotechnology
Founded1976
HeadquartersSouth San Francisco, California, United States
Key peopleIan T. Clark, CEO
Hal Barron, M.D.
Richard H. Scheller, Ph.D.
Frederick C. Kentz, III, Legal
Steve Krognes, CFO
Timothy L. Moore
Denise Smith-Hams, HR
Arthur D. Levinson, Ph.D., Chairman, Genentech Board of Directors
ProductsAvastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Xeloda, ACTEMRA, Lucentis, Xolair, Activase, Boniva, Cathflo Activase, Nutropin, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax
Owner(s)Hoffmann-La Roche
Employeesc. 12,300 (August 1, 2013)
Websitewww.gene.com
 
Jump to: navigation, search
Genentech, Inc.
TypeWholly owned subsidiary of Roche
IndustryBiotechnology
Founded1976
HeadquartersSouth San Francisco, California, United States
Key peopleIan T. Clark, CEO
Hal Barron, M.D.
Richard H. Scheller, Ph.D.
Frederick C. Kentz, III, Legal
Steve Krognes, CFO
Timothy L. Moore
Denise Smith-Hams, HR
Arthur D. Levinson, Ph.D., Chairman, Genentech Board of Directors
ProductsAvastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Xeloda, ACTEMRA, Lucentis, Xolair, Activase, Boniva, Cathflo Activase, Nutropin, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax
Owner(s)Hoffmann-La Roche
Employeesc. 12,300 (August 1, 2013)
Websitewww.gene.com

Genentech Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer.[1][2] It is considered to have founded the biotechnology industry.[1][2] Boyer is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector.[3] While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company.[1][4] Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977.[5] David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.

As of August 2013, Genentech employed more than 12,300 people.[6] The Swiss global health-care company F. Hoffmann-La Roche AG now completely owns Genentech after completing its purchase on March 26, 2009 for approximately $46.8 billion.[7][8]

Research[edit]

Genentech markets itself as a research-driven corporation that follows the science to make innovations. They employ more than 1,100 researchers, scientists and postdocs and cover a wide range of scientific activity — from molecular biology to protein chemistry to bioinformatics and physiology. Genentech scientists in these various areas of expertise currently focus their efforts on five disease categories: Oncology, Immunology, Tissue Growth and Repair, Neuroscience and Infectious Disease. Genentech's recent hiring and acquisitions indicate an intent to expand into Microbiology and Medical Imaging.

Facilities[edit]

Building 32, one of the Genentech headquarters' newer buildings

Genentech's corporate headquarters are in South San Francisco, California, with additional manufacturing facilities in Vacaville, California and in Oceanside, California. On March 17, 2006, Genentech announced its decision to construct a new fill/finish manufacturing facility with a distribution center in Hillsboro, Oregon (near Portland) which is expected to be operational by 2010. In December 2006, Genentech sold its Porrino, Spain facility to Lonza and acquired an exclusive right to purchase Lonza's mammalian cell culture manufacturing facility under construction in Singapore. In June 2007, Genentech began the construction and development of an E. coli manufacturing facility, also in Singapore, for the worldwide production of LUCENTIS (ranibizumab injection) bulk drug substance with licensure anticipated by early 2010.

Controversy[edit]

Disputes[edit]

In 2009, The New York Times reported that Genentech's talking points on health care reform made it into the official statements of several Members of Congress during the health care debate.[9]

In 1999, Genentech agreed to pay the University of California, San Francisco $200 million to settle a nine-year-old patent dispute. In 1990, UCSF sued Genentech for $400 million in compensation for alleged theft of technology developed at the university and covered by a 1982 patent. Genentech claimed that they developed Protropin, a growth hormone, independently of UCSF. A jury ruled that the university's patent was valid last July, but wasn't able to decide whether Protropin was based upon UCSF research or not. Protropin, a drug used to treat dwarfism, was Genentech's first marketed drug and its $2 billion in sales has contributed greatly to Genentech's position as an industry leader. The settlement was to be divided as follows: $30 million to the University of California General Fund, $85 million to the three inventors and two collaborating scientists, $50 million towards a new teaching and research campus for UCSF, and $35 million to support university-wide research.[10]

Products timeline[edit]

Awards and recognitions[edit]

References[edit]

  1. ^ a b c Russo, E. (2003). "Special Report: The birth of biotechnology". Nature 421 (6921): 456–457. doi:10.1038/nj6921-456a. PMID 12540923.  edit
  2. ^ a b "Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start the first biotechnology company, Genentech." Genentech. "Corporate Overview". 
  3. ^ Cohen, S.; Chang, A.; Boyer, H.; Helling, R. (1973). "Construction of biologically functional bacterial plasmids in vitro". Proceedings of the National Academy of Sciences of the United States of America 70 (11): 3240–3244. doi:10.1073/pnas.70.11.3240. PMC 427208. PMID 4594039.  edit
  4. ^ "In January 1976, 28-year-old venture capitalist Robert Swanson entered the picture. A successful cold-call at Boyer's lab led to a couple of beers — and an agreement to start a pharmaceutical company. Investing $500 each, they capitalized a new business, Genentech, to seek practical uses for Boyer and Cohen's engineered proteins. Swanson raised money for staff and labs...""Who made America? Herbert Boyer". PBS. 
  5. ^ Itakura, K.; Hirose, T.; Crea, R.; Riggs, A. D.; Heyneker, H. L.; Bolivar, F.; Boyer, H. W. (1977). "Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin". Science 198 (4321): 1056–1063. doi:10.1126/science.412251. PMID 412251.  edit
  6. ^ "Fortune Magazine 100 Best Companies to Work For 2011". CNN. Retrieved 2011-03-01. 
  7. ^ Morse, Andrew (2006-05-10). "Chugai Shares Post Healthy Gain On Prospects for Cancer Drug". The Wall Street Journal (WSJ.COM). Retrieved 2008-09-26. 
  8. ^ Staff writers (2008-07-21). "Roche Makes $43.7B Bid for Genentech". Genetic Engineering & Biotechnology News. ISSN 1935-472X. Retrieved 2008-09-26. 
  9. ^ Pear, Robert. "In House, Many Spoke with One Voice: Lobbyists", New York Times, 15 November 2009.
  10. ^ Genentech Press Release. "University of California and Genentech Settle Patent Infringement Lawsuits". Genentech Inc. Retrieved 18 October 2012. 
  11. ^ "Working Mother Magazine". 
  12. ^ "TechNet". 
  13. ^ "Nature". 
  14. ^ "Science Magazine". 
  15. ^ "ComputerWorld Magazine". 
  16. ^ "Glassdoor.com Lists Naughtiest and Nicest C.E.O.'s of 2008". The New York Times. December 26, 2008. Retrieved May 3, 2010. 
  17. ^ "The Economist". 

Further reading[edit]

External links[edit]